← Human Trials & Peer-Reviewed Studies
Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy
Plain-language guide to PMID 10411121 (1999): clinical trial study of Somatostatin in 15 patients.
Key Facts
- PMID
- 10411121
- Journal
- Thyroid : official journal of the American Thyroid Association
- Year
- 1999
- Study type
- Clinical Trial
- Authors
- Valli N et al. (8 authors)
- DOI
- 10.1089/thy.1999.9.583
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Somatostatin.
Their objective was to compare the results of SRS and conventional radiological imaging (CRI) for the diagnosis of recurrent disease and/or metastases in 15 patients who had had thyroidectomy for differentiated carcinoma (14 papillary, 1 Hurthle cell carcinoma) and who displayed elevated Tg levels (10 to 65000 ng/mL) together with negative ITBS performed after 100 mCi.
Why It Was Studied
The follow-up of patients who underwent thyroidectomy for differentiated thyroid carcinoma is based on the combination of serum thyroglobulin (Tg) measurement and radioiodine total-body scan (ITBS).
The diagnostic strategy to be used in patients with elevated serum Tg level but negative ITBS remains debatable.
Who Took Part
According to the abstract, 15 patients were involved.
The age groups tagged for this paper are children, adults, middle-aged adults and older adults, both men and women.
It was followed by computed tomography (CT) scanning and/or magnetic resonance imaging (MRI) of the neck, chest and occasionally abdomen, and 99mTc bone scintigraphy in case of negative results.
What Was Measured
The follow-up of patients who underwent thyroidectomy for differentiated thyroid carcinoma is based on the combination of serum thyroglobulin (Tg) measurement and radioiodine total-body scan (ITBS).
The diagnostic strategy to be used in patients with elevated serum Tg level but negative ITBS remains debatable.
The subject headings attached to it are Carcinoma, Papillary, Indium Radioisotopes, Iodine Radioisotopes, Lymphatic Metastasis, Radionuclide Imaging, Radiopharmaceuticals and Receptors, Somatostatin.
What This Means in Plain Language
This is a clinical trial of Somatostatin in 15 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1999 (Thyroid : official journal of the American Thyroid Association), a journal based in United States.
More context: the Somatostatin compound page, all human trials.
Our Notes on the Compound
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.